The tweet was deleted by the author.
But we saved everything 🙂.
Taysha Gene Therapies announced plans to share updates on its TSHA-102 gene therapy program, which is currently in clinical evaluation, at the Child Neurology Society Annual Meeting (CNSAM).
The company highlighted its ongoing collaboration with the scientific and clinical community as it supports efforts to advance child neurology. Detailed company progress or results related to TSHA-102 were not provided in the announcement.
View post on X Loading...
Taysha previously featured multiple encore presentations on TSHA-102 for Rett syndrome at a key neurology meeting, according to an earlier company announcement. The TSHA-102 program remains in clinical evaluation for neurological indications. The latest update follows ongoing efforts to engage with the child neurology research community.